A detailed history of Hantz Financial Services, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 78 shares of BMRN stock, worth $5,505. This represents 0.0% of its overall portfolio holdings.

Number of Shares
78
Holding current value
$5,505
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$74.43 - $92.22 $5,805 - $7,193
78 New
78 $6,000
Q1 2024

Aug 06, 2024

SELL
$83.81 - $99.0 $1,005 - $1,188
-12 Reduced 13.33%
78 $7,000
Q2 2023

Aug 06, 2024

SELL
$86.68 - $100.3 $4,594 - $5,315
-53 Reduced 37.06%
90 $8,000
Q4 2022

Aug 06, 2024

SELL
$80.93 - $108.63 $3,318 - $4,453
-41 Reduced 22.28%
143 $15,000
Q3 2022

Aug 06, 2024

SELL
$82.16 - $96.94 $246 - $290
-3 Reduced 1.6%
184 $16,000
Q2 2022

Aug 06, 2024

SELL
$71.48 - $86.85 $2,072 - $2,518
-29 Reduced 13.43%
187 $15,000
Q1 2022

Aug 06, 2024

SELL
$74.28 - $92.69 $805,566 - $1.01 Million
-10,845 Reduced 98.05%
216 $17,000
Q4 2021

Aug 06, 2024

BUY
$71.72 - $91.47 $56,013 - $71,438
781 Added 7.6%
11,061 $977,000
Q3 2021

Aug 06, 2024

BUY
$74.77 - $85.47 $177,877 - $203,333
2,379 Added 30.11%
10,280 $795,000
Q2 2021

Aug 06, 2024

BUY
$75.51 - $84.79 $32,997 - $37,053
437 Added 5.85%
7,901 $659,000
Q1 2021

Aug 06, 2024

BUY
$74.73 - $90.69 $551,955 - $669,836
7,386 Added 9469.23%
7,464 $564,000
Q4 2020

Aug 06, 2024

BUY
$72.61 - $90.2 $8,350 - $10,373
115 Added 1.46%
7,973 $699,000
Q3 2020

Aug 06, 2024

BUY
$71.87 - $131.03 $52,608 - $95,913
732 Added 10.27%
7,858 $598,000
Q2 2020

Aug 06, 2024

SELL
$79.55 - $124.22 $9,784 - $15,279
-123 Reduced 1.7%
7,126 $879,000
Q1 2020

Aug 06, 2024

BUY
$71.37 - $96.85 $511,794 - $694,511
7,171 Added 9193.59%
7,249 $613,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Hantz Financial Services, Inc. Portfolio

Follow Hantz Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.